- Report
- February 2024
- 110 Pages
Global
From €4574EUR$4,750USD£3,934GBP
- Clinical Trials
- April 2024
- 100 Pages
Global
From €2889EUR$3,000USD£2,485GBP
- Report
- November 2023
- 432 Pages
Global
From €9149EUR$9,500USD£7,868GBP
- Report
- November 2023
- 230 Pages
Global
From €7223EUR$7,500USD£6,212GBP
- Report
- January 2021
- 600 Pages
United States
From €2696EUR$2,800USD£2,319GBP
- Report
- January 2022
- 112 Pages
Global
From €4574EUR$4,750USD£3,934GBP
- Report
- January 2022
- 160 Pages
Global
From €9149EUR$9,500USD£7,868GBP
- Report
- June 2019
- 679 Pages
Global
€21186EUR$22,000USD£18,221GBP
- Drug Pipelines
- January 2018
- 17 Pages
Global
From €9630EUR$10,000USD£8,282GBP
- Report
- August 2019
- 212 Pages
Global
From €10588EUR$10,995USD£9,106GBP
- Report
- January 2021
- 124 Pages
Global
From €3467EUR$3,600USD£2,982GBP
- Report
- April 2023
- 129 Pages
Global
€4815EUR$5,000USD£4,141GBP
Darolutamide is a novel androgen receptor inhibitor used in the treatment of prostate cancer. It is a non-steroidal anti-androgen that works by blocking the action of androgens, such as testosterone, in the body. Darolutamide is used in combination with other drugs to treat advanced prostate cancer that has spread to other parts of the body. It is also used to delay the progression of the disease in men who have not yet received chemotherapy. Darolutamide is taken orally, usually twice a day.
Darolutamide is a relatively new drug in the prostate cancer market, but it has been gaining traction due to its efficacy and safety profile. It has been shown to be well tolerated and to have fewer side effects than other drugs used to treat prostate cancer.
Some companies in the Darolutamide market include Bayer, Astellas Pharma, and Orion Corporation. Show Less Read more
